Welcome to our dedicated page for Exicure SEC filings (Ticker: XCUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Exicure, Inc. filings document a clinical-stage biotechnology issuer centered on burixafor (GPC-100) and hematologic disease development, along with the corporate governance and financing matters that support that operating structure. Its 8-K reports include financial results, liquidity disclosures, research and development expense trends, and clinical or regulatory events tied to the burixafor Phase 2 program and related license and collaboration arrangements.
Other filings record director and executive management changes, audit committee appointments, material agreements, shareholder voting matters, and capital-structure disclosures. Exicure's public records also describe intercompany financing activity involving KC Creation Co., Ltd. convertible bonds and the company's acquisition-related shift from its historical nucleic acid therapy platform to a hematologic-disease pipeline.
Exicure, Inc. (XCUR) reported 2025 annual meeting results. Stockholders elected two Class II directors to serve until the 2028 annual meeting. Sangjin Yeo received 3,481,839 votes for and 1,039 withheld; Aejin Hwang received 3,481,839 for and 1,039 withheld. There were 293,024 broker non-votes and no abstentions for Proposal 1.
Stockholders ratified CBIZ CPAs P.C. as the independent auditor for the year ending December 31, 2025, with 3,750,205 votes for, 12,485 against, and 13,212 abstentions. The advisory vote on executive compensation was approved with 3,478,408 votes for, 3,931 against, and 539 abstentions, with 293,024 broker non-votes.
Exicure, Inc. reported Q3 2025 results marked by continued losses and tight liquidity. The company recorded no revenue and a net loss of $2.437 million for the quarter. Operating expenses were $2.391 million, led by $1.499 million in general and administrative costs and $0.888 million in research and development following the GPCR USA acquisition. Other items included a $155 thousand gain on settlement of payables and a $246 thousand increase in the fair value of contingent consideration.
Cash and cash equivalents were $4.438 million as of September 30, 2025, and management stated there is substantial doubt about the ability to continue as a going concern without additional financing. Year to date, results reflect a prior gain on early lease termination of $5.974 million and cash outflows from the acquisition of GPCR USA. The balance sheet includes intangible assets of $3.784 million and goodwill of $3.340 million from that deal, and a contingent consideration liability of $5.787 million tied to milestones, including $242 thousand classified as current. Common shares outstanding were 6,373,869 as of September 30, 2025.
Exicure, Inc. (XCUR) announced quarterly results via an 8‑K. On November 7, 2025, the company reported that a press release detailing financial and operational results for the quarter ended September 30, 2025 was furnished under Item 2.02. The press release is included as Exhibit 99.1 and, as furnished information, is not deemed filed under Section 18 of the Exchange Act or incorporated by reference unless specifically stated. The filing was signed by Chief Executive Officer Andy Yoo.
Form 3 filed for EXICURE, Inc. (XCUR) by reporting person Hwang Aejin, identified as a Director. The event date is 09/08/2025. The filing states that no securities are beneficially owned by the reporting person. The form is signed by an attorney-in-fact, Andy Yoo, dated 09/29/2025. The document is an initial Section 16 filing disclosing relationship and ownership status only.
EXICURE, INC. (XCUR) director Yeo Sangjin filed an Initial Statement of Beneficial Ownership (Form 3) reporting no securities beneficially owned as of the 09/08/2025 event date. The filing was submitted on 09/29/2025 and signed by an attorney-in-fact. The form indicates the report was filed by one reporting person and that the reporting person holds the role of Director with no direct or indirect holdings disclosed.
Exicure, Inc. provides proxy details for its annual meeting, including voting procedures, quorum and director elections. There were 6,317,816 shares outstanding, so a quorum requires more than 4,158,909 shares. Two Class II directors are nominated for re-election; Class II nominees Aejin Hwang and Sangjin Yeo were appointed to the Board and to the Audit Committee on September 8, 2025, with Mr. Yeo named Audit Committee Chair. Mr. Yoo and Mr. Baik were designated to the Board by HiTron under a securities purchase agreement. The Audit Committee reviewed the 2024 audited financial statements and recommended inclusion in the 2024 Form 10-K. The Company reported a substantial decrease in net loss from 2024 to 2023, attributing the prior year’s higher costs to separation payments and related expenses. Several late Section 16 filings were disclosed. Proxy votes are revocable prior to the vote and Broadridge will serve as inspector of elections.
Exicure, Inc. provides proxy details for its annual meeting, including voting procedures, quorum and director elections. There were 6,317,816 shares outstanding, so a quorum requires more than 4,158,909 shares. Two Class II directors are nominated for re-election; Class II nominees Aejin Hwang and Sangjin Yeo were appointed to the Board and to the Audit Committee on September 8, 2025, with Mr. Yeo named Audit Committee Chair. Mr. Yoo and Mr. Baik were designated to the Board by HiTron under a securities purchase agreement. The Audit Committee reviewed the 2024 audited financial statements and recommended inclusion in the 2024 Form 10-K. The Company reported a substantial decrease in net loss from 2024 to 2023, attributing the prior year’s higher costs to separation payments and related expenses. Several late Section 16 filings were disclosed. Proxy votes are revocable prior to the vote and Broadridge will serve as inspector of elections.
Exicure HiTron Inc. reports owning 3,333,333 shares of Exicure, Inc. common stock, equal to approximately 52.8% of the outstanding shares based on 6,317,793 shares outstanding as of August 5, 2025. The filing amends prior Schedule 13D disclosures and reports corporate actions: on September 8, 2025 four directors resigned and, after nomination by the Reporting Person, the board appointed two nominees so that a majority of the board remains composed of the Reporting Person's nominees. The Reporting Person made no other share transactions in the prior 60 days. Separately, on September 18, 2025 Exicure HiTron entered into Share Pledge Agreements, pledging 1,600,000 shares as collateral to two creditors in connection with a private placement of convertible bonds; voting and dividend rights on the pledged shares remain with the Reporting Person unless an event of default occurs.
Exicure HiTron Inc. reports owning 3,333,333 shares of Exicure, Inc. common stock, equal to approximately 52.8% of the outstanding shares based on 6,317,793 shares outstanding as of August 5, 2025. The filing amends prior Schedule 13D disclosures and reports corporate actions: on September 8, 2025 four directors resigned and, after nomination by the Reporting Person, the board appointed two nominees so that a majority of the board remains composed of the Reporting Person's nominees. The Reporting Person made no other share transactions in the prior 60 days. Separately, on September 18, 2025 Exicure HiTron entered into Share Pledge Agreements, pledging 1,600,000 shares as collateral to two creditors in connection with a private placement of convertible bonds; voting and dividend rights on the pledged shares remain with the Reporting Person unless an event of default occurs.
Exicure HiTron Inc. reports owning 3,333,333 shares of Exicure, Inc. common stock, equal to approximately 52.8% of the outstanding shares based on 6,317,793 shares outstanding as of August 5, 2025. The filing amends prior Schedule 13D disclosures and reports corporate actions: on September 8, 2025 four directors resigned and, after nomination by the Reporting Person, the board appointed two nominees so that a majority of the board remains composed of the Reporting Person's nominees. The Reporting Person made no other share transactions in the prior 60 days. Separately, on September 18, 2025 Exicure HiTron entered into Share Pledge Agreements, pledging 1,600,000 shares as collateral to two creditors in connection with a private placement of convertible bonds; voting and dividend rights on the pledged shares remain with the Reporting Person unless an event of default occurs.
Exicure HiTron Inc. reports owning 3,333,333 shares of Exicure, Inc. common stock, equal to approximately 52.8% of the outstanding shares based on 6,317,793 shares outstanding as of August 5, 2025. The filing amends prior Schedule 13D disclosures and reports corporate actions: on September 8, 2025 four directors resigned and, after nomination by the Reporting Person, the board appointed two nominees so that a majority of the board remains composed of the Reporting Person's nominees. The Reporting Person made no other share transactions in the prior 60 days. Separately, on September 18, 2025 Exicure HiTron entered into Share Pledge Agreements, pledging 1,600,000 shares as collateral to two creditors in connection with a private placement of convertible bonds; voting and dividend rights on the pledged shares remain with the Reporting Person unless an event of default occurs.
Exicure, Inc. reported significant changes to its Board of Directors. On September 8, 2025, the company appointed Sangjn Yeo and Aejin Hwang as Class II directors, with terms running until the 2025 annual meeting of stockholders or until a successor is elected and qualified. Both were also named to the audit committee, and Mr. Yeo was appointed Chairman of that committee.
The filing states there are no family relationships between the new directors and existing leadership, and no material related-party transactions requiring disclosure. Each new director will receive an annual retainer of $20,000 and is expected to enter into the company’s standard indemnification agreement.
Also on September 8, 2025, four directors — Ho Jung John, Chang Keun Choi, Sangwook Song, and Minwoo Kang — resigned from the Board, effective immediately. Their resignations were not due to any disagreement about the company’s operations, policies, or practices. After these appointments and resignations, Exicure has four remaining vacancies on its Board.
Insider tax-withholding triggered on vested RSUs: Joshua Miller, Chief Accounting Officer and a director at Exicure, Inc. (XCUR), reported a disposition of 316 shares of common stock on 08/16/2025 at a price of $6.65 per share. The Form 4, signed 08/20/2025, indicates these shares were withheld by the company to satisfy the reporting person's tax withholding obligations upon RSU vesting rather than sold on the open market. Following the withholding, the filing reports 316 shares beneficially owned by Mr. Miller.
Exicure, historically a nucleic-acid therapeutics company, completed the acquisition of GPCR USA and recorded identifiable intangible assets of $3.8M and $3.34M of goodwill. GPCR USA is running a Phase 2 trial of GPC-100 plus propranolol for stem cell mobilization and completed dosing of 20 patients, with results targeted for the fourth quarter of 2025. The acquisition included contingent consideration with a fair value of $5.541M tied to clinical and commercial milestones.
On the balance sheet, total assets were $18.738M with cash and cash equivalents of $7.858M (down from $12.508M). The company reported a quarterly net loss of $2.621M and an accumulated deficit of $198.875M, while six‑month net income of $0.389M reflected a $5.974M gain on early lease termination. Management discloses substantial doubt about the company’s ability to continue as a going concern and states additional financing is required.